Dilated Cardiomyopathy, Heart Failure, Lef Ventricular Dysfunction
Conditions
Brief summary
The purpose of this study is to determine whether electrocardiogram, echocardiography, cardiac MRI, sera biomarkers can improve early detection of myocardial involvement and clinical outcome.
Detailed description
A cohort of 100 patients with mutations in the dystrophin gene associated with Becker muscular dystrophy and/or dilated cardiomyopathy will be included (patients with Duchenne muscular dystrophy are excluded). Patients with undergo at baseline the following workups: electrocardiogram, echocardiography, cardiac MRI, sera biomarkers measurement. At 3 years and 5 years, patients will be investigated according to the same protocol and occurrence of cardiac adverse events in the meanwhile will be recorded. Statistical analysis will assess correlations between cardiac phenotype and DMD mutations and prognostic value of cardiac investigations.
Interventions
PROCEDUREECG, echocardiography, cardiac MRI, sera biomarkers
Sponsors
Institut de Myologie, France
Karim WAHBI
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* mutation in the DMD gene * Becker muscular dystrophy and/or dilated cardiomyopathy * age\>18 years * affiliation to the French medical insurance
Exclusion criteria
* Duchenne muscular dystrophy * Any other chronic disease that may be associated with heart disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular ejection fraction | 3 years |
Secondary
| Measure | Time frame |
|---|---|
| Composite endpoint: hospitalisation for heart failure, death due to heart failure | 3 years |
Countries
France
Contacts
Primary ContactKarim Wahbi, MD, PhD
Outcome results
None listed